Doug Dieterich

5.7k total citations · 1 hit paper
25 papers, 4.1k citations indexed

About

Doug Dieterich is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Doug Dieterich has authored 25 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hepatology, 13 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in Doug Dieterich's work include Hepatitis C virus research (17 papers), Liver Disease Diagnosis and Treatment (8 papers) and Hepatitis B Virus Studies (6 papers). Doug Dieterich is often cited by papers focused on Hepatitis C virus research (17 papers), Liver Disease Diagnosis and Treatment (8 papers) and Hepatitis B Virus Studies (6 papers). Doug Dieterich collaborates with scholars based in United States, United Kingdom and Spain. Doug Dieterich's co-authors include Mark Sulkowski, Francesca J. Torriani, Nathan Clumeck, Richard K. Sterling, Ricard Solà, Diethelm Messinger, Mark Nelson, David L. Thomas, Eduardo Lissen and Julio Montaner and has published in prestigious journals such as The Lancet, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Doug Dieterich

24 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡

2006 3.5k citations Richard K. Sterling, Eduardo Lissen et al. Hepatology profile →

Peers

Doug Dieterich

EPIDE

HEPAT

SURGE

EDM

Eduardo Lissen Spain

Anaïs Vallet‐Pichard France

Joan Genescà Spain

Alejandro Soza Chile

Alessandra Mangia Italy

Evangelos Akriviadis Greece

Guillaume Pénaranda France

Tse–Ling Fong United States

Helen S. Te United States

Ramazan Idılman Türkiye

Eduardo Lissen Spain

Doug Dieterich

4.2k ×1.2

EPIDE

3.6k ×1.2

HEPAT

447 ×0.9

SURGE

424 ×1.0

EDM

730 ×2.3

Citations per year, relative to Doug Dieterich Doug Dieterich (= 1×) peers Eduardo Lissen

Countries citing papers authored by Doug Dieterich

Since Specialization

Citations

This map shows the geographic impact of Doug Dieterich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doug Dieterich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doug Dieterich more than expected).

Fields of papers citing papers by Doug Dieterich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doug Dieterich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doug Dieterich. The network helps show where Doug Dieterich may publish in the future.

Co-authorship network of co-authors of Doug Dieterich

This figure shows the co-authorship network connecting the top 25 collaborators of Doug Dieterich. A scholar is included among the top collaborators of Doug Dieterich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doug Dieterich. Doug Dieterich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bacon, B., Michael P. Curry, Doug Dieterich, et al.. (2017). Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network. Journal of Hepatology. 66(1). S726–S726. 9 indexed citations

Curry, Michael P., B. Bacon, Doug Dieterich, et al.. (2017). Utilization of sofosbuvir/velpatasvir in genotype 2–6 HCV: real-world experience from the TRIO network. Journal of Hepatology. 66(1). S58–S58. 2 indexed citations

Younossi, Zobair M., B. Bacon, Michael P. Curry, et al.. (2017). Elbasvir/Grazoprevir effectiveness in patients with Chronic Hepatitis C and Chronic Kidney Disease: real-world experience from the TRIO Network. Journal of Hepatology. 66(1). S748–S749. 2 indexed citations

Curry, Michael P., Bruce R. Bacon, Doug Dieterich, et al.. (2016). EFFECTIVENESS OF 12 OR 24 WEEK LDV/SOF AND 12 WEEK LDV/SOF+RBV IN TREATMENT-EXPERIENCED PATIENTS WITH CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK. Value in Health. 19(3). A312–A313. 3 indexed citations

Curry, Michael P., Bruce R. Bacon, Doug Dieterich, et al.. (2016). EFFECTIVENESS OF 8 OR 12 WEEK LDV/SOF IN TREATMENT-NAÏVE PATIENTS WITH NON-CIRRHOTIC, GENOTYPE 1 HEPATITIS C: REAL-WORLD EXPERIENCE FROM THE TRIO NETWORK. Value in Health. 19(3). A313–A313. 7 indexed citations

Dieterich, Doug, B. Bacon, Michael P. Curry, et al.. (2016). Ledipasvir/Sofosbuvir+/−Ribavirin in Patients Co-Infected with HCV and HIV: Real-World Heterogeneous Population from the Trio Network. Journal of Hepatology. 64(2). S756–S757. 1 indexed citations

Dieterich, Doug, Bruce R. Bacon, Steven L. Flamm, et al.. (2015). P0775 : Final evaluation of 955 HCV patients treated with 12 week regimens containing sofosbuvir +/- simeprevir in the trio network: Academic and community treatment of a real-world, heterogeneous population. Journal of Hepatology. 62. S621–S621. 34 indexed citations

Kowdley, Kris V., B. Bacon, Doug Dieterich, et al.. (2015). P0867 : Efficacy evaluation of 24 week SOF + RBV in a heterogeneous, real-world population of genotype 3 HCV patients; Data from the trio network. Journal of Hepatology. 62. S665–S666. 1 indexed citations

Molina, Jean‐Michel, Susanna Naggie, Mark Sulkowski, et al.. (2014). COL01-03: PHOTON-1 : association sofosbuvir-ribavirine pour l’infection à VHC de génotypes 1 à 3 chez des patients co-infectés par le VIH. Médecine et Maladies Infectieuses. 44(6). 1–2. 1 indexed citations

10.

Naggie, Susanna, Mark Sulkowski, Anuj Gaggar, et al.. (2014). P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS. Journal of Hepatology. 60(1). S475–S476. 1 indexed citations

11.

Joshi, Deepak, John O’Grady, Doug Dieterich, Brian Gazzard, & Kosh Agarwal. (2011). Increasing burden of liver disease in patients with HIV infection. The Lancet. 377(9772). 1198–1209. 222 indexed citations

12.

Fiel, Maria Isabel, et al.. (2010). 551 INTRAHEPATIC CCCDNA BURDEN AND SEVERITY OF HEPATIC FIBROSIS IN PATIENTS WITH HBV-ASSOCIATED HCC. Journal of Hepatology. 52. S220–S220. 1 indexed citations

13.

Sterling, Richard K., Eduardo Lissen, Nathan Clumeck, et al.. (2006). Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡. Hepatology. 43(6). 1317–1325. 3450 indexed citations breakdown →

14.

Torriani, Francesca J., JK Rockstroh, M. Rodríguez‐Torres, et al.. (2004). 92 Final week-72 results of the aids pegasys ribavirin international co-infection trial (APRICOT): A randomized, partially blinded, multinational comparative trial of peginterferon ALFA-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) vs interferon ALFA-2A(IFN). Journal of Hepatology. 40. 33–33. 11 indexed citations

15.

Rodríguez‐Torres, M., Francesca J. Torriani, E Lissén, et al.. (2004). 507 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV/HIV co-infection: Results from the aids pegasys ribavirin international co-infectio (abstract withdrawn). Journal of Hepatology. 40. 149–149. 4 indexed citations

16.

Nerad, Judith L., et al.. (2003). General Nutrition Management in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases. 36(s2). S52–S62. 36 indexed citations

17.

Dieterich, Doug, Michael A. Poles, E A Lew, et al.. (1997). Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. Antimicrobial Agents and Chemotherapy. 41(6). 1226–1230. 7 indexed citations

18.

Dieterich, Doug, E A Lew, Donald P. Kotler, Michael A. Poles, & J M Orenstein. (1994). Treatment with Albendazole for Intestinal Disease Due to Enterocytozoon bieneusi in Patients with AIDS. The Journal of Infectious Diseases. 169(1). 178–183. 126 indexed citations

19.

Dieterich, Doug, et al.. (1993). Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction.. PubMed. 88(4). 542–8. 38 indexed citations

20.

Dieterich, Doug, et al.. (1992). Gastrointestinal pneumocystosis in HIV-infected patients on aerosolized pentamidine: report of five cases and literature review.. PubMed. 87(12). 1763–70. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact